Recombinant Human TSH-Mediated Management of Differentiated Thyroid Cancer

Simple item page
dc.contributor.authorCharoonsak Somboonpornen_US
dc.date.accessioned2011-02-24T04:34:34Z
dc.date.available2011-02-24T04:34:34Z
dc.date.created2011-01-08en_US
dc.date.issued2011-01-08en_US
dc.description.abstractRoles of recombinant human TSH (rhTSH) has been extensively studied during the past ten years in the management of patients with differentiated thyroid cancer.  Since it is convenient, safe and equally effective in the treatment with radioactive iodine and in the follow-up procedures after treatment, rhTSH has been used increasingly and is now considered a method to replace the conventional thyroid hormone withdrawal in the management of patients with differentiated thyroid cancer.  This review article aims to provide the evidence regarding the use of rhTSH in various aspects of taking care of this kind of patients, both in terms of treatment of the disease and follow-up of the disease. en_US
dc.identifier.citationSrinagarind Medical Journal (SMJ); Vo. 25 No. 4 October-December 2010; 328-335en_US
dc.identifier.urihttps://imsear.searo.who.int/handle/123456789/134098
dc.language.isoen_USen_US
dc.publisherFaculty of Medicine, Khon Kaen Universityen_US
dc.rightsAcademic Affairs, Faculty of Medicine, Khon Kaen University, KhonKaen, Thailanden_US
dc.source.urihttps://thailand.digitaljournals.org/index.php/SMJ/issue/archiveen_US
dc.source.urihttps://thailand.digitaljournals.org/index.php/SMJ/article/view/4618en_US
dc.titleRecombinant Human TSH-Mediated Management of Differentiated Thyroid Canceren_US
dc.typeReview Articlesen_US
Files
Collections
Srinagarind Medical Journal